Open access
Open access
Powered by Google Translator Translator

Covid-19

New COVID drugs face delays as trials grow more difficult.

24 Jun, 2022 | 11:47h | UTC

New COVID drugs face delays as trials grow more difficult – Nature

 


Perspective | Four areas of health innovation boosted by the pandemic.

24 Jun, 2022 | 11:36h | UTC

Four areas of health innovation boosted by the pandemic – Nature Medicine

 

Commentary on Twitter

 


Cohort Study: COVID-19 trajectories among 57 million adults in England.

24 Jun, 2022 | 11:34h | UTC

COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records – The Lancet Digital Health

News Release: Most comprehensive analysis of COVID-19 data reveals previously unattributed deaths – Health Data Research UK

 

Commentary from one of the authors on Twitter (thread – click for more)

 


Ivermectin for COVID-19 Cochrane review update: 11 trials and no evidence of benefit shown.

23 Jun, 2022 | 10:38h | UTC

News Release: Ivermectin for COVID-19 review update: 11 trials and no evidence of benefit shown – Liverpool School of Tropical Medicine

Original Article: Ivermectin for preventing and treating COVID‐19 – Cochrane Library

Summary: Ivermectin for preventing and treating COVID-19 – Cochrane Library

 


Systematic Review: SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19.

23 Jun, 2022 | 10:37h | UTC

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 – Cochrane Library

Summary: Are laboratory-made COVID-19-specific monoclonal antibodies effective to prevent COVID-19 in adults? – Cochrane Library

 


Risk factors for SARS-CoV-2 related severe Multisystem Inflammatory Syndrome in Children investigated in a Swedish population-based study.

23 Jun, 2022 | 10:36h | UTC

News Release: Risk factors for severe COVID-19 complication in children investigated in Swedish population-based study – Karolinska Institutet

Original Study: Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children – The Lancet Regional Health Europe

 


ASA and APSF statement on perioperative testing for the COVID-19 virus.

22 Jun, 2022 | 12:19h | UTC

ASA and APSF Statement on Perioperative Testing for the COVID-19 Virus – American Society of Anesthesiologists

Commentary: ASA, APST Update Perioperative SARS-CoV-2 Testing Recommendations – HealthDay

Related:

Surgical Triage and Timing for Patients with COVID: A Guidance Statement from the Society of Thoracic Surgeons – Annals of Thoracic Surgery

When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA – Langenbeck’s Archives of Surgery

Guideline Update: Timing of elective surgery and risk assessment after SARS-CoV-2 infection – “The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting”.

Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of Covid-19.

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

BJS commission on surgery and perioperative care post-COVID-19.

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

 


Review: SARS-CoV-2 infection and COVID-19 vaccination in pregnancy.

22 Jun, 2022 | 12:09h | UTC

SARS-CoV-2 infection and COVID-19 vaccination in pregnancy – Nature Reviews Immunology

 


Cohort Study: Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA.

22 Jun, 2022 | 12:07h | UTC

Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases – The Lancet

Commentaries:

COVID-19 mRNA vaccination and myocarditis or pericarditis – The Lancet

Myocarditis and Pericarditis After the COVID-19 mRNA Vaccination – American College of Cardiology

Related:

SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents – JAMA Cardiology

Myocarditis and pericarditis after COVID-19 vaccination: clinical management guidance for healthcare professionals – UK Health Security Agency

Myocarditis following a third Pfizer vaccination dose in military recruits in Israel.

Myocarditis following COVID-19 BNT162b2 vaccination among adolescents in Hong Kong.

[Preprint] Post-marketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12-39 years in Italy.

Myocarditis after BNT162b2 vaccination in Israeli adolescents.

Myocarditis cases reported after mRNA-Based COVID-19 vaccination in the US from December 2020 to August 2021.

A case-control study showed an increased risk of myocarditis after COVID-19 vaccination with a messenger RNA vaccine compared to an inactivated virus vaccine.

[Preprint] Risk of myocarditis following sequential COVID-19 vaccinations by age and sex.

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination vs. SARS-CoV-2 infection.

Case series with 139 adolescents and young adults with suspected myocarditis following mRNA vaccination showed most cases had a mild clinical course and rapid resolution of symptoms.

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 


Review: Sex differences in sequelae from COVID-19 infection and in long COVID syndrome.

22 Jun, 2022 | 12:06h | UTC

Sex differences in sequelae from COVID-19 infection and in long COVID syndrome: a review – Current Medical Research and Opinion

Commentary: Women more likely to have long COVID, different symptom profile – CIDRAP

 


Comparing the Pfizer and Moderna Covid vaccines for young children.

22 Jun, 2022 | 12:02h | UTC

Comparing the Pfizer and Moderna Covid vaccines for young children – STAT

Related: FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

 


How common is long COVID? Why studies give different answers.

21 Jun, 2022 | 11:03h | UTC

How common is long COVID? Why studies give different answers – Nature

 


WHO Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines.

20 Jun, 2022 | 10:42h | UTC

Interim statement on decision-making considerations for the use of variant updated COVID-19 vaccines – World Health Organization

See also: Interim statement on the composition of current COVID-19 vaccines – World Health Organization

 

Commentary on Twitter (thread – click for more)

 


Case-control study: Risk of long COVID associated with delta vs. omicron variants of SARS-CoV-2.

20 Jun, 2022 | 10:34h | UTC

Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 – The Lancet

News Release: Long COVID risk less during Omicron compared to Delta, study finds – King’s College London

Commentaries:

Expert reaction to study looking at long COVID prevalence associated with delta versus omicron variants of SARS-CoV-2 – Science Media Centre

Omicron less likely to lead to long COVID, study finds – CIDRAP

Covid-19: Long covid risk is lower with omicron than delta, researchers find – The BMJ

 

Commentary on Twitter

 


Consensus Study: A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research.

20 Jun, 2022 | 10:31h | UTC

A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study – The Lancet Respiratory Medicine

News Release: Key outcomes of Long COVID identified in international consensus study – King’s College London

Invited Commentary: Post-COVID-19 condition in children: a COS is urgently needed – The Lancet Respiratory Medicine

 

Commentary on Twitter

 


Clues to long Covid: Scientists strive to unravel what is driving disabling symptoms.

20 Jun, 2022 | 10:30h | UTC

Clues To Long Covid – Science

 


[Preprint] Open-label RCT: Baricitinib noninferior to Tocilizumab in hospitalized patients with severe COVID-19.

20 Jun, 2022 | 10:28h | UTC

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv

Related:

Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

WHO recommends two new drugs to treat COVID-19 – World Health Organization

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 


Test-negative, case–control study: Effects of previous infection and vaccination on symptomatic omicron infections.

17 Jun, 2022 | 11:44h | UTC

Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections – New England Journal of Medicine

Commentary: Qatar Omicron-wave study shows slow decline of natural immunity, rapid decline of vaccine immunity – Weill Cornell Medicine

Related:

Hybrid immunity: a combination of vaccination and prior infection probably offers the best protection against COVID – The Conversation

Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2 – New England Journal of Medicine

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity – Environmental Research

Two new studies show vaccination provides additional protection after Covid-19 infection.

 

Commentary on Twitter

 


FDA advisers OK COVID-19 vaccines for youngest kids.

17 Jun, 2022 | 11:43h | UTC

FDA advisers OK COVID-19 vaccines for youngest kids – CIDRAP

See also: FDA advisers endorse 1st COVID-19 shots for kids under 5 – Associated Press

 


Perspective | Viruses that were on hiatus during Covid are back — and behaving in unexpected ways.

16 Jun, 2022 | 11:06h | UTC

Viruses that were on hiatus during Covid are back — and behaving in unexpected ways – STAT

 


Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations.

15 Jun, 2022 | 11:22h | UTC

Pfizer’s Paxlovid study fails to answer key questions over benefit for broader populations – STAT

 


Analysis of thromboembolic and thrombocytopenic events after the AstraZeneca, Pfizer, and Moderna COVID-19 vaccines in 3 Nordic countries.

15 Jun, 2022 | 11:17h | UTC

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open

 


Phase 2 RCT: Safety and immunogenicity of the AstraZeneca vaccine in children aged 6–17 years.

15 Jun, 2022 | 11:15h | UTC

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial – The Lancet

Invited Commentary: Increasing children’s global access to COVID-19 vaccines – The Lancet

 


Systematic Review: Janus kinase inhibitors for the treatment of COVID‐19.

14 Jun, 2022 | 11:14h | UTC

Janus kinase inhibitors for the treatment of COVID‐19 – Cochrane Library

Summary: Are systemic Janus kinase inhibitors an effective treatment for people with COVID-19? – Cochrane Library

 


[Preprint] RCT: Ivermectin does not benefit patients with mild-to-moderate COVID-19 in the outpatient setting.

14 Jun, 2022 | 11:12h | UTC

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial – medRxiv

Commentary: Study finds no benefit to taking ivermectin for COVID-19 symptoms – Duke University

 


Stay Updated in Your Specialty

No spam, just news.